Abstract submission is now closed.
Note for abstract presenters:
The maximum size for posters is: Height 4 feet (121 cm); width 3 feet (91 cm).
All poster abstracts will be printed in the final program. Posters will be displayed during the entire meeting, from Thursday, December 6 until Sunday, December 9, 1.00 p.m.
Poster presentations:
The authors can present their abstracts in the groups and order described below.
The time allocated for each poster presentation will be 4 minutes (incl. discussion).
FRIDAY, DECEMBER 7, 2007
12:15 – 13:45
PO 1. Cachexia mechanisms
PO 2. Cachexia in cancer
PO 3. Methodology studies
17:45 – 19:15
General poster discussion (with all abstract authors)
SATURDAY, DECEMBER 8, 2007
12:15 – 13:45
PO 4. Intervention studies
PO 5. Human cachexia - various
PO 6. Cachexia mechanisms
POSTER PRESENTATIONS- FRIDAY, DECEMBER 7, 2007
12.15 – 13.45
POSTER SESSION 1
Cachexia mechanisms
1.01 Prostaglandin excess is sufficient to induce adipose tissue wasting through increased substrate utilization
Vegiopoulos A1, Chichelnitskiy E1, Ostertag A1, Müller-Decker K2, Herzig S1
1Molecular Metabolic Control, 2Tumor Models, German Cancer Research Center, Heidelberg, Germany
1.02 Wnt3a promotes beta-catenin signaling and myotube formation during myogenic differentiation
Langen RC1, van der Velden JL1, Kelders MC1, Laeremans H2, Schols AM1
1Department of Respiratory Medicine, Nutrition and Toxicology Research Institute, Maastricht University, Maastricht, Netherlands; 2Department of Pharmacology and Toxicology, Maastricht University, Maastricht, Netherlands
1.03 Protein breakdown, mitochondria homeostasis, energy balance and muscle wasting
Mammucari C1, Masiero E1, Romanello V2, Milan G2, Sandri M2
1Venetian Institute of Molecular Medicine, Padova, Italy; 2Dulbecco Telethon Institute at Venetian Institute of Molecular Medicine, Padova, Italy
1.04 Proteasome inhibitor MG 132 has different effect on protein metabolism under in vivo and in vitro conditions
Holecek M, Muthny T, Kovarik M, Sispera L
Department of Physiology, Charles University Medical Faculty, Hradec Kralove, Czech Republic
1.05 The ubiquitin-proteasome and the apoptotic pathways are sequentially up- and down- regulated during atrophy and recovery following immobilization in rat gastrocnemius muscles
Vazeille E, Claustre A, Taillandier D, Bechet D, Attaix D, Combaret L
Human Nutrition Unit, INRA, Ceyrat, France
1.06 Uncoupling skeletal muscle damage and regeneration during cachexia: a cellular mechanism underlying muscle wasting?
Coletti D1, Berardi E1, Aulino P1, Molinaro M1, Sassoon D2, Adamo S1
1Sapienza University of Rome, Rome, Italy; 2UMR S 787 - Groupe Myologie INSERM - UPMC Paris VI, Paris, France
1.07 Hsp70 overexpression inhibits NF-kappaB activation and skeletal muscle atrophy
Senf SM, Dodd SL, Judge AR
Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL, USA
1.08 Identification of novel signaling molecules involved in muscle atrophy
Hardeland U, Vegiopoulos A, Gail AM, Lemke U, Chichelnitskiy E, Herzig S
German Cancer Research Center, Heidelberg, Germany
1.09 STAT3 mediates skeletal muscle wasting in cancer cachexia
Koniaris LG1,2 , Aydogdu T2, Guo S1, Jin X1, Zhang Z1, Zimmers TA1,2
1Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; 2Cell Biology & Anatomy, University of Miami Miller School of Medicine, Miami, FL, USA
1.10 Investigating TNF inhibition of IGF-1 signaling via JNK in cell culture models of skeletal muscle atrophy
Gebski BL1, Shavlakadze T1, Ng DCH2, Bogoyevitch MA2, Grounds MD1
1School of Anatomy and Human Biology, the University of Western Australia, Perth, WA, Australia; 2Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Vic, Australia
1.11 Mass and strength of skeletal muscles over-expressing Class 2 IGF-1 Ea isoform
Shavlakadze T1, Chai R1, Pinniger G2, Winn N3, Rosenthal N3, Grounds MD1
1School of Anatomy and Human Biology, School of Biomedical, 2Biomolecular and Chemical Sciences, the University of Western Australia, Perth, WA, Australia; 3Developmental Biology, Pasteur Institute, Paris, France; 3Mouse Biology Unit, EMBL Monterotondo Outstation, Monterotondo, Rome, Italy
1.12 Insulin-like growth factor (IGF)-I inhibits dexamethasone-induced muscle atrophy through Akt1/GSK-3beta/beta-catenin pathway
Schakman O, Kalista S, Lause P, Verniers J, Ketelslegers JM, Thissen JP
Unité de Diabétologie et Nutrition, Université catholique de Louvain, Brussels, Belgium
1.13 Myostatin blockade by deacetylase inhibitors fails to counteract muscle wasting in tumor-bearing mice
Bonetto A, Penna F, Reffo P, Minero VG, Costelli P, Baccino FM
Department of Experimental Medicine and Oncology, University of Torino, Italy
1.14 Muscle overexpression of Follistatin, an antagonist of Myostatin, causes muscle hypertrophy
Gilson H, Schakman O, Lause P, Verniers J, Thissen JP
Unité de Diabétologie et Nutrition, Université catholique de Louvain, Brussels, Belgium
1.15 Glycogen Synthase Kinase-3 beta suppresses myogenic differentiation through negative regulation of nuclear factor of activated T-cells 3
Langen RC, van der Velden JL, Kelders MC, Willems J, Schols AM
Department of Respiratory Medicine, Maastricht University, the Netherlands
1.16 Attenuation of muscle loss and proteolysis by curcumin C3 complex in MAC-16 tumor-bearing mice
Siddiqui RA1, Hassan S1, Harvey K1, Das T2, Mukerji P2, DeMichele S2
1Methodist Research Institute, Indianapolis, IN, USA; 2Abbott Nutrition, Abbott Laboratories, Columbus, OH, USA
1.17 Investigation of hormonal-inflammatory interference in cachexia through in vivo promoter mapping
Chichelnitskiy E, Vegiopoulos A, Ziegler A, Herzig S
Molecular metabolic control, German Cancer Research Center, Heidelberg, Germany
1.18 The leucine metabolite HMB: mechanics considerations influencing clinical outcomes
Baxter JH1, Kraemer WJ2, Tisdale MJ3
1Abbott Laboratories, Columbus, Ohio, USA; 2Department of Kinesiology, University of Connecticut, Storrs, CT, USA; 3Pharmaceutical Sciences, Aston University, Birmingham, UK
1.19 Identification of pro-cachectic transcription factors by cell-based high throughput screening
Gail AM1, Hardeland U1, Conkright MD2, Herzig S1
1Molecular Metabolic Control, DKFZ, Heidelberg, Germany; 2Scripps Research Institute, Jupiter, Florida, USA
1.20 Chemotherapy related fatigue: an ex vivo mouse model for skeletal muscle impairment
van Norren K1, van Tuijl S1, Arts K1, Haagsman H2, van der Beek E1, van Helvoort A1
1Numico Research, Wageningen, The Netherlands; 2Faculty of Veterinary Medicine, Utrecht University, The Netherlands
POSTER SESSION 2
Cachexia in cancer
2.21 Body composition and functional performance characteristics of newly diagnosed cancer patients with and without weight loss
Kilgour R1, Vigano AA2, Trutschnigg B2, Hornby L2, Bacon S1, Morais JA3
1Department of Exercise Science, Concordia University, Montreal, Quebec, Canada; 2McGill University, Palliative Care Division, Montreal, Quebec, Canada; 3Division of Geriatrics, McGill University Health Centre, Montreal, Quebec, Canada
2.22 Bioelectrical impedance analysis (BIA) and survival in advanced cancer
Seyidova-Khoshknabi D, Kirkova J, Lasheen W, Davis MP, Walsh D, Lagman R
The Harry R. Horvitz Center for Palliative Medicine, Taussig Cancer Center, Cleveland Clinic Health System, Cleveland, OH, USA
2.23 Daily physical-rest activity in cancer cachexia in relationship to nutritional state, metabolism and quality of life
Fouladiun M1, Körner U1, Gunnebo L1, Sixt-Ammilon P2, Bosaeus I2, Lundholm K1
1Department of Surgery, Sahlgrenska University Hospital, Göteborg Sweden; 2Department of Clinical Nutrition, Sahlgrenska University Hospital, Göteborg Sweden
2.24 Secondary causes of weight loss in patients with cancer cachexia
Del Fabbro E, Dalal S, Li Z, Freer G, Bruera E
M.D. Anderson Cancer Center, Houston, USA
2.25 Functional muscle testing may detect early cancer cachectic muscle degeneration
Krakowski-Roosen H1, Kinscherf R2, Renk H1, Hildebrandt W3, Martignoni ME4, Weber MA5
1Div. G100 (Translational Oncology), German Cancer Research Center, Heidelberg, Germany; 2Anatomy and Developmental Biology, University of Heidelberg, Germany;3Div. D020 (Immunochemistry), German Cancer Research Center, Heidelberg, Germany; 4Dept. of General Surgery, University of Heidelberg, Germany; 5Div. E010 (Radiology), German Cancer Research Center, Heidelberg, Germany
2.26 C-reactive protein: a potential predictor of early cachexia in lung cancer?
Mehrfar P1, Altit G2, Walker E1, Chevalier S
1School of Dietetics and Human Nutrition, McGill University,Montreal, Quebec, Canada; 2Medicine, McGill University, Montreal, Quebec, Canada
2.27 Skeletal muscle mass regulation in mildly weight-losing cancer patients
Op den Kamp CMH1, Minnaard R2, Kelders MC1, Hesselink MK2, Langen RC1, Schols AM1
1Department of Respiratory Medicine, Nutrim, Maastricht University, Maastricht, The Netherlands; 2Department of Movement Sciences, Nutrim, Maastricht University, Maastricht, The Netherlands
2.28 Body composition and exercise intolerance in non-small cell lung cancer.
Paland M1, Mori Y1, Karhausen T3, Misgeld C1, Kuhnke A2, Felger D1, Koch A1, Suttorp N2, Anker SD1, Rauchhaus M1, 3
1Applied Cachexia Research, Dept. of Cardiology, Charité University Hospital Berlin, Germany; 2Department of Infectious Diseases and Pulmonary Medicine, Charité University Hospital Berlin, Germany; 3Dept. of Cardiology, Charité University Hospital Berlin, Germany
2.29 Fat loss and lipid metabolism in advanced cancer patients
Perrine M2, Pawlowicz M1, Mourtzakis M2, Lieffers JR1, Prado C1, Clandinin MT1, Baracos VE 1,2, Mazurak VC1
1Alberta Institute for Human Nutrition, Department of Agricultural, Food and Nutritional Science, Faculty of Agriculture, Forestry and Home Economics, University of Alberta, Edmonton, Alberta, Canada; 2Department of Oncology, Division of Palliative Care Medicine, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada
2.30 Cachectic colorectal cancer patients show anabolic resistance of muscle signaling and protein turnover to amino acid availability without elevated whole body or muscle proteolysis
Rennie MJ, Atherton P, Patel R, Larvin M, Liptrot S, Lund JN, Rankin D, Selby A, Smith K, Wilkes E
University of Nottingham School of Graduate Entry Medicine and Health, Derby City Hospital, Derby, UK
2.31 Systemic inflammation and muscle quality in cancer cachexia
Stephens NA1, Skipworth RJE1, Greig CA1, Gray CD2, Ross JA1, Fearon KCH1
1School of Clinical and Surgical Sciences (Surgery), University of Edinburgh, Edinburgh, UK; 2Dept of Medical Physics, University of Edinburgh, Edinburgh, UK
2.32 A mass spectrometric approach to the discovery of protein biomarkers in the urine of patients with gastroesophageal cancer and cachexia
Skipworth RJE1, Stewart GD1, Bhana M1, Christie J2, Cronshaw AD2, Fearon KCH1, Ross JA1
Repair Group, University of Edinburgh, Edinburgh, UK; 2Institute of Structural and Molecular Biology, University of Edinburgh, Edinburgh, UK
2.33 Plasma levels of macrophage inhibitory cytokine-1 in patients with gastro-oesophageal cancer: association with systemic inflammation
Skipworth RJE1, Brown DA2, Hunter M2, Breit SN2, Ross JA1, Fearon KCH1
1Clinical and Surgical Sciences (Surgery), School of Clinical Sciences and Community Health, The University of Edinburgh, UK; 2Centre for Immunology, St. Vincent's Hospital and University of New South Wales, Sydney, Australia
2.34 Real-imaging cDNA-AFLP gene expression profiling reveals new insights into muscle cachexia development of pancreatic cancer patients
Skorokhod A1, Krakowski-Roosen H2, Martignoni ME3, von Kalle C2
1Institute of Molecular Biology and Genetics, Ukrainian Academy of Sciences, Kiev, Ukraine; 2German Cancer Research Center, Heidelberg, Germany; 3Department of Surgery, European Pancreas Center, University of Heidelberg, Germany
2.35 Lower intramuscular free amino acids, carnosine and glutathione with reduced myofibrillar protein in cachectic compared to non-cachectic patients with pancreatic cancer
Schmitt TL1, Martignoni ME2, Kinscherf R3, Friess H2, Hildebrandt W4
1Division of Immunochemistry (D020) German Cancer Reserach Center, Heidelberg, Germany; 2Department of Surgery, Klinikum rechts der Isar, Technical University, Munich, Germany; 3Institute of Anatomy and Developmental Biology, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany; 4University of Nottingham, School of Graduate Entry Medicine and Health, Derby City Hospital, Derby, UK
2.36 Fatigue in pancreatic cancer: the potential link between exertional dyspnea, exercise limitation, skeletal musculature and neurohormonal activation.
Heinz C1, Mori Y1, Springer J1, Karhausen T1, Stieler J3, Doehner W2, Oettle H3, Dietz R2, Anker SD1, Rauchhaus M2
1Department of Cardiology, Applied Cachexia Research, Charité Universitätsmedizin Berlin, Germany; 2Department of Cardiology, Charité Universitätsmedizin Berlin, Germany; 3Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Germany
2.37 Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer
Skipworth RJE1, Moses AGW1, Voss AC2, Anderson RA3, Ross JA1, Fearon KCH1
1Clinical and Surgical Sciences (Surgery), The University of Edinburgh, Edinburgh, UK; 2Ross Products Division, Abbott Nutrition Research & Development Abbott Laboratories, Columbus, Ohio, USA; 3MRC Human Reproductive Sciences Unit, The University of Edinburgh, Edinburgh, UK
2.38 Tertiary cachexia: psycho-social factors that contribute to the problems caused by cancer cachexia syndrome
Hopkinson JB, Foster C, Wright DNM, Okamoto I
Macmillan Research Unit, School of Nursing and Midwifery, University of Southampton, Southampton, Hampshire, UK
2.39 Living with cancer cachexia: exploring the perspectives of patients and their significant others
Reid J
Cancer Centre, Belfast City Hospital / Queens University Belfast, Belfast, Ireland
POSTER SESSION 3
Methodology studies
3.40 The role of measuring REE in the diagnosis and treatment of cachectic states
Vaisman N1, Niv E2, Lusthaus M2, Comaneshter D3
1Tel Aviv Sourasky Medical Center and Tel Aviv Sackler Medical School, Tel Aviv, Israel; 2Clinical Nutrition Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 3Statistic Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
3.41 Validation study of inflammatory-based prognostic score in terminal cancer
Chiang D1, Glare PA2, Clarke SJ3, Clark K2, Adelstein S4, Sharpe L5
2Palliative Care, 3Oncology, 5Psychology, Sydney Cancer Centre, 1University of Sydney, NSW, Australia; 4Immunology, RPAH, Camperdown, NSW, Australia
3.42 How precise is BIA in cachexia
Davis M, Seyidova-Khoshknabi D, Kirkova J, Walsh DT, Lasheen W, Lagman R, LeGrand S
The Harry R. Horvitz Center for Palliative Medicine, Taussig Cancer Center, Cleveland Clinic Health System, Cleveland, Ohio, USA
3.43 Bioelectrical impedance analysis is a valid and accurate method to assess body composition in hemodialysis patients, correlating well to dual-energy X-ray absorptiometry
Rustom R1, Wiedemann J2, Djurhuus CB3, El Nahas M4
1Division of Metabolic & Cellular Medicine, School of Clinical Sciences, University of Liverpool, Liverpool , United Kingdom; 2Dept. of Biostatistics, Global Development, Novo Nordisk; 3hGH APCD Management, Global Development, Novo Nordisk; 4Sheffield Kidney Institute, University of Sheffield, Northern General Hospital, Sheffield, United Kingdom
3.44 Precision of dual energy X-ray absorptiometry and bioelectrical impedence in patients with advanced cancer
Vigano AAL1, Trutschnigg B1, Morais JA2, Lucar E1, Kilgour R3, Rosenthall L4
1McGill University, Palliative Care Division, Montreal, Quebec, Canada; 2McGill University Health Centre, Division of Geriatrics, Montreal, Quebec, Canada; 3Concordia University, Exercise Science, Montreal, Quebec, Canada; 4McGill University Health Centre, Radiology Department, Montreal, Quebec, Canada
3.45 Does a nutritional assessment tool correlate to laboratory values indicating cachexia in lung cancer patients?
Gioulbasanis I1, Giannousi Z1, Tsatsanis C2, Margioris A2, Mavroudis D1, Georgoulias V1,
1Department of Clinical Oncology, University Hospital of Crete, Herakleion, Greece; 2Department of Clinical Chemistry-Biochemistry, University Hospital of Crete, Herakleion, Greece
3.46 Validation of a simplified anorexia questionnaire
Kirkova J, Davis M, Yavuzsen T, Walsh D, LeGrand S, Lagman R
The Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic, Cleveland, OH, USA
3.47 Assessing quadriceps muscle strength in newly-diagnosed, advanced cancer patients: test-retest reliability and correlational analyses
Reinglas J1, Kilgour R1, Hornby L2, Trutschnigg B2, Rosenthall L3, Vigano AA2
1Department of Exercise Science, Concordia University, Montreal, Quebec, Canada; 2McGill University, Palliative Care Division, Montreal, Quebec, Canada; 3Department of Radiology, McGill University Health Centre, Montreal, Quebec, Canada
3.48 Handgrip dynamometry measurements in elderly cancer patients: a comparison of two instruments (JAMAR versus BIODEX)
Trutschnigg B1, Kilgour R2, Reinglas J2, Rosenthall L3, Hornby L1, Vigano AA1,
1McGill University, Palliative Care Division, Montreal, Quebec, Canada; 2Department of Exercise Science, Concordia University, Montreal, Quebec, Canada; 3Department of Radiology, McGill University Health Centre, Montreal, Quebec, Canada
POSTER PRESENTATIONS- SATURDAY, DECEMBER 8, 2007
POSTER SESSION 4
Intervention studies
4.49 A soluble activin receptor type IIB increases muscle mass in a mouse model of androgen deprivation therapy
Lachey J, Pullen AE, Wong V, Haigis B, Ucran J, Pearsall RS
Acceleron Pharma, Inc, Cambridge, MA, USA
4.50 Effects of CRF2R agonist on tumour growth and cachexia in mice bearing the Lewis lung carcinoma
Argilés JM1, Figueras M1, Ametller E1, Fuster G1, Olivan M1, Fontes de Oliveira CC1, F. J. López-Soriano FJ1, Isfort RJ2, Busquets S1
1Cancer Research Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Spain; 2Procter & Gamble Pharmaceuticals, Mason Business Center, Mason, USA
4.51 Selective androgen receptor modular (SARM) prevents body weight and muscle loss in tumor-bearing mice
Okolicany J1, Veverka K2, Steiner MS3, Dalton JT4
1Drug Discovery, GTx Inc., Memphis, TN, USA; 2Preclinical Development, GTx Inc., Memphis, TN, USA; 3CEO, GTx Inc., Memphis, TN, USA; 4Preclinical R&D, GTx Inc., Memphis, TN, USA
4.52 Attenuation of mouse colon adenocarcinoma CT-26-induced cachexia by Chinese herbal medicine extract in BALB/c mice
Chen BS, Kao WY, Lai TH, Chung YS, Sui PN, Wu RY
Chinese Herbal Medicine Project, Development Center for Biotechnology, Taipei 221, Taiwan
4.53 Fenofibrate (Tricor) exacerbates muscle wasting in a mouse model of cancer cachexia
Aydogdu T1, Guo S2, Koniaris LG1,2, Zimmers TA1,2
1Department of Cell Biology and Anatomy, University of Miami School of Medicine, Miami, FL, USA; 2Department of Surgery, University of Miami School of Medicine, Miami, FL, USA
4.54 Ghrelin improves body weight loss associated with angiotensin II-induced cachexia in mice
Sugiyama M, Yamaki A, Furuya M
Biomedical Research Laboratories, Asubio Pharma Co., LTD., Osaka, Japan
4.55 AKT-dependent insulin signaling is enhanced in skeletal muscle and reduced in liver following in vivo ghrelin administration
Barazzoni R, Zanetti M, Cattin MR, Vinci P, Cattin L, Guarnieri G
Clinica Medica - Dept of Clinical, Morphological and Technological Sciences - University of Trieste, Italy
4.56 Effects of beta-hydroxy-beta-methylbutyrate treatment on protein metabolism in rat skeletal muscle
Kovarik M, Muthny T, Sispera L, Holecek M
Department of Physiology, Medical Faculty, Charles University, Hradec Kralove, Czech Republic
4.57 Lithium administration modulates muscle GSK3-beta but does not prevent muscle loss in experimental cancer cachexia
Sonni PV1, Iannuzzi S1, Aversa Z1, Frascaria T1, Costelli P2, Rossi Fanelli F1, Muscaritoli M1
1Clinical Medicine, University "La Sapienza", Rome, Italy; 2Experimental Medicine and Oncology, University of Turin, Turin, Italy
4.58 Effect of beta-hydroxy-beta-methylbutyrate on weight and muscle loss in cancer cachexia
Sonni PV1, Iannuzzi S1, Aversa Z1, Ramaccini C1, Pinto G1, Minero VG2, Costelli P2, Rossi Fanelli F1, Muscaritoli M1
1Department of Clinical Medicine, University "La Sapienza", Rome, Italy; 2Department of Experimental Medicine and Oncology, University of Turin, Italy
4.59 Endurance training restores hepatic lipid metabolism of cachectic Walker 256 tumour bearing rats
Lira FS1, Tavares FL1, Yamashita AS1, Koyama CH1, Alves MJ1, Caperuto EC1, Batista ML1,2, Seelaender Jr.& MCL1
1Molecular Biology of the Cell Group, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. 2School of Physical Education, University of Mogi das Cruzes, Brazil
4.60 Effects of proteasome inhibition in an experimental model of cancer cachexia
Reffo P1, Minero VG1, Muscaritoli M2, Costelli P1, Baccino FM1, Rossi Fanelli F2
1Dept. of Experimental Medicine and Oncology, University of Torino, Italy; 2Dept. of Clinical Medicine, University 'La Sapienza', Rome, Italy
4.61 Formoterol and roxithromycin administered individually and in combination prevent tissue wasting in a rat model of cancer cachexia
Kenley R1, Ekblom J1, Denissenko M2
1Anaborex, Inc., La Jolla, CA, USA; 2Invitrogen, Corp., Carlsbad, CA, USA
4.62 Bisoprolol in experimental cancer cachexia
Springer J1, Palus S1, Braun T1, Flach VC1, Hartmann K1, Schmidt K1, Rauchhaus M1, Argiles J2, Anker SD1
1Division of Applied Cachexia Research, Department of Cardiology, Charité Medical School, Berlin, Germany; 2Dept of Biochemistry and Molecular Biology of Cancer, University of Barcelona, Spain
4.63 The effects of xanthine oxidase inhibitors oxypurinol and allopurinol in experimental cancer cachexia
Springer J, Möller N, Palus S, Braun T, Flach VC, Hartmann K, Schmidt K, Doehner W, Anker SD
Division of Applied Cachexia Research, Department of Cardiology, Charité Medical School, Berlin, Germany
4.64 The effects of the aldosterone antagonist spironolactone in experimental cancer cachexia
Palus S, Springer J, Braun T, Flach VC, Hartmann K, Schmidt K, von Haehling S, Anker SD
Division of Applied Cachexia Research, Department of Cardiology, Charité Medical School, Berlin, Germany
4.65 Proteasome inhibition in CHF rats improves diaphragm function by restoring myosin content
van Hees HWH1, Li YP2, Dekhuijzen PNR1, Heunks LMA1
1Department of Pulmonary Diseases and Intensive Care Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; 2Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
4.66 Pharmacological intervention against TNF-alpha attenuates the increases in MuRF-1 and MaFbx mRNA in a model of cardiac cachexia
Steffen BT, Lees SJ
Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA
4.68 Proteasome inhibition improves contractility of the emphysematous hamster iaphragm
Heunks LMA1, Van Hees H1, Li YP2, Ennen LE1, Dekhuijzen PNR1
1Department of Pulmonary Diseases, University Medical Centre Nijmegen, the Netherlands; 2Dept of Medicine, Baylor College of Medicine, Houston (TX), USA
4.69 Double-blinded, placebo-controlled plasmid GHRH trial for cancer-associated anemia in dogs
Draghia-Akli R, Khan AS, Bodles-Brakhop AM, Pope MA, Brown PA
VGX Pharmaceuticals, Immune Therapeutics Division, The Woodlands, Texas, USA
4.70 Mirtazapine and appetite in advanced cancer
Kirkova J, Davis MP, Walsh D, Lagman R, Bennani-Baiti N, Seyidova-Khoshknabi D
The Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic, Cleveland, Ohio, USA
4.71 Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutritional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: interim results
Mantovani G, Madeddu C, Gramignano G, Serpe R, Massa E, Dessì M, Macciò A
Department of Medical Oncology, University of Cagliari, Italy
POSTER SESSION 5
Human cachexia - various
5.72 Disuse atrophy reduces muscle protein synthesis in the fasted and fed state in humans
Glover EI1, Phillips SM1, Tang JE1, Oates BR1, Tarnopolsky MA2, Smith K3, Selby A3, Rennie MJ3
1Kinesiology and 2Pediatrics, McMaster University, Hamilton, Ontario, Canada; 3University of Nottingham, School of Biomedical Sciences, Derby City General Hospital, Derby, UK
5.73 The effect of weight loss on mobility and frailty in the community-dwelling elderly
Vandewoude MFJ1, Hoeck S1, Geerts J1, Van Hal G1, Van der Heyden J2, Breda J1
1University of Antwerp, Belgium; 2Scientific Institute of Public Health, Belgium
5.74 Muscle quality is maintained in healthy old women: influence of muscle volume optimisation
Greig CA, Gray CD, Fearon KCH, Beggs , Lewis SJ, Young A
School of Clinical Sciences and Community Health, University of Edinburgh, UK
5.75 Cytokines and their association with functional parameters in older persons – A pilot study using a biochip with high sensitivity for cytokine measurements
Bauer JM1, Wagner JT1, Cupic D1, Bertsch T2, Braun S3, Sieber CC1
1Department for Geriatric Medicine, University of Erlangen-Nuremberg, Germany; 2Institute of Clinical Chemistry, Nuremberg Hospital, Germany; 3Institute of Laboratory Medicine, German Heart Centre, Munich, Germany
5.76 Cachexias: a 2007 state of the art review of the metabolic and biochemical abnormalities in different clinical models of cachexia
Bennani-Baiti N, Walsh D, Davis MP
The Harry R. Horvitz Center for Palliative Medicine, Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA
5.77 Natriuretic peptide- and catecholamine-induced lipolysis in cardiac cachectic patients
Tedeschi S, Cremaschi E, Cabassi A
Department Internal Medicine, Nephrology and Health Science, University of Parma, Parma, Italy
5.78 Differences in body mass changes after the onset of heart failure symptoms. Impact on body composition, biochemical characteristics and prognosis.
Rozentryt PJ1, Nowak JU1, von Heahling S2, Sikora J1, John A1, Wilczek U1, Poloński L1, Anker SD2
1III Department of Cardiology, Silesian Centre for Heart Diseases, Zabrze, Poland; 2Applied Cachexia Research, Charite Campus Virchow-Klinikum, Berlin, Germany.
5.79 Upregulation of STAT-3, SOCS-1, pro-inflammatory and anti-inflammatory circulating cytokine mRNA gene expression in CHF patients with and without cachexia compared to healthy control subjects
Sandek A1, Wüst J1, von Haehling S1, Szabó T1, Bauditz J2, Swidsinski A2, Doehner W1, Rauchhaus M1, Lochs H2, Anker SD*1, Volk HD*3
1Division of Applied Cachexia Research, Department of Cardiology, Charite, Campus Virchow-Klinikum, Berlin, Germany; 2Department of Gastroenterology, Charite, Campus Mitte, Berlin, Germany; 3Department of Medical Immunology, Charite, Campus Mitte, Berlin, Germany
5.80 Direct medical costs of HIV wasting: a retrospective analysis of a national managed care database
Siddiqui J1, Meletiche D2, Phillips AL2, Freedland E2
1University of California, Davis, Sacramento, USA; 2EMD Serono, Inc., Rockland, MA, USA
5.81 Hypermuscularity does not abrogate burn injury induced muscle wasting
Cheung MC, Spalding PB, Gutierrez JC, Namias N, Koniaris LG, Zimmers TA
Department of Surgery, University of Miami, Miami, FL, USA
5.82 Nutrition management of patients with major burns
Cernea D, Vladoianu NAM, Novac MB, Stoica M
Intensive Care, Clinical Emergency Hospital Craiova, Romania
5.83 Metabolic and nutritional aspects of traumatic injury in critically traumatic patients
Vladoianu NAM1, Comanescu A2, Cernea D1
1Intensive Care, Clinical Emergency Hospital Craiova, Romania; 2Department of Obstetrics and Gynecology, Clinical Emergency Hospital Craiova, Romania
5.84 Reversibility of cachexia and course of exercise capacity over 1 year after heart-, lung- or kidney-transplantation
Habedank D1 , Kung T1, Karhausen T1, Ewert R3, Hetzer R3, Reinke P2, Anker SD1
1Applied Cachexia Research, Charité Campus Virchow, Berlin, Germany; 2Dept. Nephrology, Charité Campus Virchow, Berlin, Germany; 3Dept. Cardiothoracic Surgery, German Heart Institute, Berlin, Germany
5.85 Exercise capacity and body composition after renal transplantation of living donors: changes over time
Kung T1 , Habedank D1, Karhausen T1, Reinke P2, Anker SD1
1Division of Applied Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany; 2Department of Nephrology, Charité Campus Virchow-Klinikum, Berlin, Germany
5.86 Plasma high- but not low-molecular weight adiponection is positively associated with resting energy expenditure in male non-diabetic hemodialysis patients
Barazzoni R1, Stulle M1, Panzetta G2, Biolo G1, Zanetti M1, Guarnirei G1
1Clinica Medica - Dept of Clinical, Morphological and Technological Sciences, University of Trieste, Italy: 2Division of Nephrology, Azienda Ospedaliera "Ospedali Riuniti", Trieste, Italy
5.87 Pathogenic mechanisms of muscle loss in patients undergoing liver transplantation
Iannuzzi S1, Costelli P2, Merli M3, Bonetto A2, Gentili F3, Rossi M3, Aversa S1, Sonni PV1, Giusto M3, Tommasi V1, Rossi Fanelli F1, Muscaritoli M1
1Department of Clinical Medicine, University "La Sapienza", Rome, Italy; 2Department of Experimental Medicine and Oncology, University of Turin, Turin, Italy; 3Centro Trapianti Policlinico Umberto I, University "La Sapienza", Rome, Italy
POSTER SESSION 6
Cachexia mechanisms
6.88 Animal models for cancer cachexia: What are the options?
Bennani-Baiti N, Walsh D
The Harry R. Horvitz Center for Palliative Medicine, Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA
6.89 Effect of cancer cachexia upon the balance pro and anti-inflammatory cytokines in the adipose tissue of trained rats
Lira FS1, Yamashita AS1, Rosa JC2, Koyama CH1, Batista Jr. ML1,3, Seelaender MCL1
1Molecular Biology of the Cell Group, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; 2Department of Physiology, Federal University of São Paulo, São Paulo, Brazil; 3School of Physical Education, University of Mogi das Cruzes, São Paulo, Brazil
6.90 New insights into adipose atrophy in cancer cachexia
Bing C1, Russell S2, Tisdale MJ2, Jenkins JR1
1School of Clinical Sciences, University of Liverpool, Liverpool, UK; 2School of Life and Health Sciences, Aston University, Birmingham, UK
6.91 Serine-protease activity is increased in experimental cancer cachexia
Aversa Z1, Costelli P2, Sonni P1, Iannuzzi S1, Ramaccini C1, Pinto G1, Frascaria T1, Rossi Fanelli F1, Citro G3, Muscaritoli M1
1Department of Clinical Medicine, University "La Sapienza", Rome, Italy; 2Department of Experimental Medicine and Oncology, University of Turin, Turin, Italy; 3Regina Elena Institute for the Study and Cure of Cancer, Rome, Italy
6.92 The IGF-1 signaling pathway is not down-regulated in cancer cachexia
Penna F1, Bonetto A1, Costelli P1, Muscaritoli M2, Rossi Fanelli F2, Baccino FM1
1Dipartmento di Medicina e Oncologia Sperimentale, Università di Torino,Torino, Italy; 2Dipartmento di Medicina Clinica, Università La Sapienza, Roma, Italy
6.93 Genetic and pharmacologic inhibition of myostatin for muscle preservation in cancer cachexia
Link M1, Aydogdu T2, Guo S1, Koniaris LG3, Zimmers TA3
1Surgery; 2Cell Biology & Anatomy; 3Surgery, Cell Biology & Anatomy, University of Miami Miller School of Medicine, Miami, FL, USA
6.94 Impaired immune function in an animal model for cancer cachexia prior to weight loss
van Helvoort A1, Faber J1, Kegler D1, Vos P1, Garssen J1,2
1Numico Research, Wageningen, The Netherlands; 2Department of Pharmacology & Pathophysiology, Utrecht University, The Netherlands
6.95 Impaired daily activity and muscle function in cachectic C26 adenocarcinoma bearing mice
van Norren K, Kegler D, Luiking YC, Gorselink M, van der Beek EM, van Helvoort A
Numico Research, Wageningen, The Netherlands
6.96 Metabolomics of cancer cachexia
Ardeshirpour F1, O'Connell TM2, Asher SA1, George JR1, Guttridge DC3, Couch ME1
1Otolaryngology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 2Molecular Pharmaceutics, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 3Human Cancer Genetics, Ohio State University, Columbus, Ohio, USA
6.97 The obesity paradox in dogs with spontaneously-occurring heart failure
Slupe JL, Freeman LM, Rush JE
Department of Clinical Sciences, Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA
 |
Program
